Vision
Culture
Team
Pipeline
Pipeline Overview
Clinical Trials
Technologies
AdAPT™ Platform
CyNRGY™ (RRx-001)
News
Press Releases
Media
Conferences
Blog
Blog
Careers
Contact Us
Select Page
< Back
RRx-001 is a phase III aerospace-derived small molecule that immunonormalizes the tumor microenvironment
Oct 28, 2021
ASCO-SITC Clinical Immuno-Oncology Symposium, Feb 28th – Mar 2nd 2019